A Randomized Placebo Controlled, Double-blind Phase II Study to Explore the Safety, Efficacy and Pharmacokinetics of Sonlicromanol in Children With Genetically Confirmed Mitochondrial Disease
Latest Information Update: 30 May 2024
At a glance
- Drugs Sonlicromanol (Primary)
- Indications Mitochondrial disorders
- Focus Therapeutic Use
- Acronyms KHENERGYC
- Sponsors Khondrion
- 27 May 2024 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
- 27 May 2024 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2025.
- 27 May 2024 Status changed from recruiting to active, no longer recruiting.